Market news

Detailed price information for Anteris Technologies Global Corp (AVR-Q) from The Globe and Mail including charting and trades.

Detailed price information for Anteris Technologies Global Corp (AVR-Q) from The Globe and Mail including charting and trades.

Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has appointed experienced financial executive Brent Moen as chief financial officer, effective September 12, 2026 AEST. Moen brings more than 25 years of leadership experience across public and private companies, with expertise spanning...

MINNEAPOLIS and BRISBANE, Australia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, is pleased to advise that Vice Chairman and Chief Executive Officer, Wayne Paterson, will be presenting at the Cantor Global Healthcare Conference, the Wells Fargo 21st Annual Healthcare Confere

Detailed price information for Anteris Technologies Global Corp (AVR-Q) from The Globe and Mail including charting and trades.

MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update. Q2 2026 Highlights Secured U.S. Medicare reimbursement eligibility for the global pivotal P

Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) made progress on its pivotal PARADIGM Trial during the June quarter, enrolling and treating its first US patients after securing Medicare reimbursement eligibility for qualifying procedures. The company also expanded recruitment across...

A $10 billion transcatheter aortic valve replacement (TAVR) market can still be an underdeveloped disease category. Aortic stenosis narrows the heart's aortic valve, restricting blood flow from the heart to the rest of the body. Despite the severity of the disease, Anteris Technologies estimates that only about 20% of patients with the condition currently receive treatment. Recent national analyses showing rising aortic stenosis mortality among adults ages 55 to 64 further suggest that underdiag